The Flow Cytometry Core Facility (FCCF) at the Moffitt Cancer Center was established in 1990 to provide a centralized flow cytometry service for Cancer Center members. Flow cytometry is an indispensable analytical tool for cell biology, immunology and translational research efforts at the Cancer Center. This technology provides a means for rapidly and accurately analyzing multiple characteristics of biological particles, as well as an ability to rapidly isolate and purify cell populations of interest for the purpose of assessing immunological functions and molecular distinctions, cell culture cloning and animal transplantation studies. The FCCF is staffed with highly trained instrument specialists with a combined 36 years of research-based flow cytometry experience. The facility houses six bench-top analyzers, two cell sorters, a bead array analyzer, an automated bead sorter and a fluorescent microscope. This includes the most recently added BD Biosciences customized LSR II analyzer, which was added in response to increased demand for sophisticated polychromatic analyses and high throughput capability. Its customized optical bench has expanded services to the Moffitt investigators doing novel, cutting-edge cancer biology studies. Fifty-six funded members routinely access the FCCF, which is up from thirty-nine in the 2006 review period. In 2008, the FCCF began to use the Laboratory Information Management System (LIMS) to consolidate usage tracking, scheduling, and billing. Flow LIMS also provides a secure repository for Core project data that is accessible by the Pl and the laboratory staff. The FCCF provides critical support for the scientific programs at the Cancer Center by providing investigators with access to state-of-the-art instrumentation, cutting-edge cytometry applications and an exceptionally well trained staff. Overall usage in the FCCF has increased over 30% since the 2006 CCSG submission. The Core requests CCSG Support of $57,049, which is 24% of its operational budget. Over 93% of usage is by Moffitt members and peer-reviewed.
The FCCF provides Moffitt Members a high-quality, state-of-the-art facility that has consistently met investigators'demands for flow cytometry. The core provides researchers with a well-managed, cost-effective facility that functions as a repository for centralized technical expertise, sophisticated instrumentation and software, as well as educational and training opportunities.
|Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221|
|Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110|
|Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805|
|Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314|
|Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315|
|Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513|
|Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139|
|Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587|
|Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539|
|Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :|
Showing the most recent 10 out of 1254 publications